Kernel

Kernel is a US neurotechnology company founded by Bryan Johnson that develops non-invasive brain measurement devices, including the Kernel Flow (time-domain fNIRS) and Kernel Flux (MEG) systems. The company's neuroimaging technology is used in the PREDICT trial, which investigates brain activity biomarkers for predicting response to depression interventions including ketamine.